Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

JOURNAL ARTICLE published August 2014 in Annals of Oncology

Research funded by European Union Framework (278659)

Authors: S. Loi | S. Michiels | R. Salgado | N. Sirtaine | V. Jose | D. Fumagalli | P.-L. Kellokumpu-Lehtinen | P. Bono | V. Kataja | C. Desmedt | M.J. Piccart | S. Loibl | C. Denkert | M.J. Smyth | H. Joensuu | C. Sotiriou